Intranasal Dental Midazolam Review Found High Bias Across All Included Studies

A review reporting no significant route difference does not establish that routes are equivalent.

What the supplied source reports

Thirteen studies comparing intranasal midazolam with other administration routes during pediatric dental care met the review criteria. All thirteen were judged at high risk of bias, with problems involving blinding, concealment or outcome assessment. The review did not identify a statistically significant difference in behavior or sedation levels across the available comparisons.

Limits of the evidence

The studies were small and heterogeneous. Some route comparisons, including intravenous and rectal midazolam against intranasal use in routine dental care, were absent. Failure to detect a difference with weak evidence cannot exclude clinically meaningful differences in onset, distress or adverse events.

Implications for forensic interpretation

For a dental sedation opinion, specify the route, formulation and intended endpoint rather than generalizing from midazolam as a drug name. The review mainly explains uncertainty. It does not demonstrate equal absorption or allow success with one route to guarantee performance or safety with another.

Source and related reading

Source reviewed: Sedative and Behavioral Effects of Intranasal Midazolam in Comparison with Other Administrative Rout (PMC8237818). Forensic applications above are interpretive analysis of the supplied publication.

Related reading: Dementia Dental Sedation Included Airway Events Despite Reduced Doses.